Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Marketed since 1967 it has been found the drug "can cause problems for a baby's development, including birth defects and ...

Sanofi will handle global commercialization of the therapy. The Big Pharma is paying RadioMedix and Orano Med 100 million euros upfront and committing up to 220 million euros in sales milestones for ...

Panacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High ...

Panacea Biotec initially filed the lawsuit in May 2021, seeking to stop Sanofi from marketing its Shan6 vaccine, which it ...

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage ...

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...

(Reuters) -Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV) therapy, the ...

Sanofi will gain exclusive rights to commercialize the lead-212-based radiopharmaceutical AlphaMedix in somatostatin-expressing neuroendocrine cancers.

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...